Key Data Related to Plexxikon's Lead Oncology Program PLX4032 to be Presented at ECCO15 / ESMO34 2009 Conference
Berkeley, CA - September 10, 2009 – Plexxikon Inc., today announced that key clinical data related to PLX4032 will be presented in an oral presentation at the ECCO 15 / ESMO 34 2009 Congress. The European CanCer Organisation (ECCO) and the European Society for Medical Oncology (ESMO) Joint Multidisciplinary Congress will be held in Berlin, Germany from September 20-24.
The PLX4032 abstract was chosen as a “best abstract” to be featured in one of five Presidential sessions, and will be highlighted as part of ECCO/ESMO’s official media program.
The presentation information is as follows:
- Abstract #6BA: “Early efficacy signal demonstrated in advanced melanoma in a phase I trial of the oncogenic BRAF-selective inhibitor PLX4032”
- Oral presentation to be made on September 24, 2009, 10:15 a.m. CET by Paul Chapman, M.D., attending physician, melanoma/sarcoma service, Memorial Sloan-Kettering Cancer Center, in the Presidential Session IV.
Information about the content of the abstract is strictly embargoed to 11:15 a.m.(CET) on Wednesday, 23 September 2009.
About PLX4032 (RG7204) — A Personalized Medicine for Cancer Treatment
PLX4032 is a novel, oral small molecule for the treatment of melanoma and other cancers harboring the V600E mutation of the BRAF kinase gene. This defect is present in approximately 50 percent of melanoma skin cancers, 10 percent of colorectal cancers and about eight percent of all solid tumors. Plexxikon and Roche are co-developing PLX4032 under their 2006 license and collaboration agreement. A companion diagnostic also is being co-developed along side of PLX4032 to determine the BRAF mutation status of patients.
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche’s personalized healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients.
In 2008, Roche had over 80,000 employees worldwide and invested almost 9 billion Swiss francs in R&D. The Group posted sales of 45.6 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com.
Plexxikon is a leader in the structure-guided discovery and development of novel small molecule pharmaceuticals to treat human disease. The company’s clinical stage programs include PLX4032 for the treatment of melanoma and colorectal cancer, PLX5568 for the treatment of polycystic kidney disease, PLX204 for the treatment of diabetes and PLX3397 for the treatment of metastatic disease and rheumatoid arthritis. Among the company’s preclinical development programs, candidates are being developed for the treatment of rheumatoid arthritis, multiple sclerosis and other autoimmune diseases as well as for the treatment of other cancers.
Plexxikon’s proprietary Scaffold-Based Drug Discovery™ platform integrates multiple state-of-the-art technologies, including structural screening as one key component that provides a significant competitive advantage over other drug discovery approaches. To date, the company has discovered a portfolio of clinical and preclinical stage compounds being developed to address significant unmet medical needs in cardio-renal disease, CNS disorders, inflammatory and neuro-inflammatory diseases and oncology.